Table 3 Demographics and clinical features of 37 patients with ABPA (n = 37).

From: Eosinophils may serve as CEA-secreting cells for allergic bronchopulmonary aspergillosis (ABPA) patients

Clinical parameters

Number (proportion)

Age (years)

55.00 ± 15.96

Gender (male/female)

24 (64.86%) /13 (35.14%)

Symptom

Cough

37 (100.00%)

Expectoration

29 (78.38%)

Hemoptysis

7 (18.92%)

Short of breath

20 (54.05%)

Heat

5 (13.51%)

Comorbidities

Asthma

13 (35.14%)

COPD

9 (24.32%)

Interstitial lung disease

4 (10.81%)

Bronchiectasis

28 (75.68%)

Treatment

Voriconazole

9 (24.32%)

Voriconazole and glucocorticoid

14 (37.84%)

Glucocorticoid

4 (10.81%)

Itraconazole and glucocorticoid

9 (24.32%)

Itraconazole

1 (2.70%)

Ending

Relief or (and) stability

21 (56.76%)

Relapse or (and) progression

16 (43.24%)